Scandion Oncology udvikler anti-cancer lægemidler
26 June 2019 - 17:36Scandion Oncology udvikler lægemidler, som kan blokere eller omgå resistens overfor anti-cancer lægemidler. Administrerende direktør Nils præsenterer firmaet for investorer....
Scandion Oncology A/S
Scandion Oncology A/S is a biotechnology company with the mission to address one of the most important challenges in modern oncology - the effective treatment of cancer which has developed resistance towards existing cancer medicine. Its first-in-class lead compound, SCO-101, is an add-on to chemotherapy and is currently in clinical phase I and II studies in cancer patients. The company also has s...Learn more about company